Regent Peak Wealth Advisors LLC Sells 31 Shares of Eli Lilly and Company (NYSE:LLY)

Regent Peak Wealth Advisors LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLYFree Report) by 1.2% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,640 shares of the company’s stock after selling 31 shares during the quarter. Regent Peak Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,539,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Thompson Investment Management Inc. bought a new stake in Eli Lilly and Company in the 3rd quarter worth about $27,000. Retirement Group LLC boosted its position in Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after purchasing an additional 35 shares during the last quarter. Legacy Financial Group LLC purchased a new position in Eli Lilly and Company in the third quarter worth about $35,000. Optiver Holding B.V. purchased a new position in Eli Lilly and Company in the third quarter worth about $36,000. Finally, Cornerstone Planning Group LLC purchased a new position in Eli Lilly and Company in the second quarter worth about $33,000. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,538 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $631.81, for a total value of $21,821,453.78. Following the completion of the sale, the insider now directly owns 99,719,884 shares in the company, valued at approximately $63,004,019,910.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 195,055 shares of company stock worth $125,254,657 in the last quarter. 0.13% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on LLY. Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research report on Monday. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, DZ Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research report on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $700.00.

Check Out Our Latest Analysis on LLY

Eli Lilly and Company Trading Up 0.4 %

LLY traded up $3.41 during trading hours on Tuesday, reaching $763.96. 2,552,667 shares of the company’s stock traded hands, compared to its average volume of 3,221,156. The firm has a 50-day moving average price of $739.63 and a 200 day moving average price of $641.00. Eli Lilly and Company has a 52-week low of $342.30 and a 52-week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $725.88 billion, a PE ratio of 131.72, a PEG ratio of 1.71 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLYGet Free Report) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the business earned $2.09 EPS. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. As a group, sell-side analysts predict that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Articles

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.